CLAIMS

1. A composition comprising
   i) a GLP-1 agonist,
   ii) a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) and
   iii) a hydrotrope, wherein the hydrotrope is capable of increasing the solubility of SNAC at least 5-fold or such as at least 10-fold.

2. The composition according to claim 1, wherein the hydrotrope is Nicotinamide or Resorcinol.

3. The composition according to any of the previous claims, wherein the ratio of salt of NAC/hydrotrope (w/w) is 0.5-10, such as 0.5-8 or such as 0.5-5.

4. The composition according to any of the previous claims, wherein the composition further comprising a lubricant selected from magnesium stearate and glyceryl dibehenate.

5. The composition according to any of the previous claims, wherein the GLP-1 agonist comprises at least one albumin binding substituent.

6. The composition according to any of the previous claims, wherein the GLP-1 agonist is selected from the group consisting of: liraglutide, semaglutide, GLP-1 agonist B and GLP-1 agonist C.

7. The composition according to any of the previous claims, wherein the salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC) is the sodium salt of of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (SNAC).

8. The composition according to any of the previous claims, wherein the composition is a solid composition.

9. The composition according to any of the above claims consisting of:
   i) a GLP-1 agonist, such as Semaglutide, GLP-1 agonist B or GLP-1 agonist C.
   ii) a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), such as the sodium salt of NAC (SNAC)

iii) nicotinamide or resorcinol and

iv) a lubricant.

10. The composition according to any of the above claims, wherein a unit dosage comprises

i) 0.1-30 mg, such as 0.1-20 mg GLP-1 agonist, such as Semaglutide, GLP-1 agonist B or GLP-1 agonist C.

ii) 50-600 mg salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid (NAC), such as the sodium salt of NAC (SNAC) and

iii) 20-200 mg nicotinamide

iv) 0-10 mg lubricant.

11. The composition according to any of the previous claims wherein the composition is a pharmaceutical composition for oral administration.

12. The composition according to any of the previous claims, wherein the composition is a pharmaceutical composition for use in a method of treating diabetes and/or obesity.

13. A method for producing a solid pharmaceutical composition comprising the steps of;

i) obtaining a blend comprising a salt of NAC and a hydrotrope,

ii) co-processing the blend of i) and

iii) preparing said solid pharmaceutical composition using the product of ii).

14. A method for producing a solid pharmaceutical composition comprising the steps of;

i) obtaining a blend comprising a salt of NAC and a hydrotrope,

ii) heat melt extruding the blend of i),

iii) milling the extrudate of ii) and

iv) preparing said solid pharmaceutical composition using the product of iii).

15. A method for producing a solid pharmaceutical composition comprising the steps of

i) obtaining a blend comprising a salt of NAC and a hydrotrope,

ii) heat melt extruding the blend of i),

iii) admixing the extrudate of ii) with an active pharmaceutical ingredient and optionally any further excipients and

iv) preparing said solid pharmaceutical composition using the mixture of iii).